InsidersTradesSigma
Track the Vericel Corp stock price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Vericel Corp has published 232 public disclosures. Market capitalisation: €2.3bn. The latest transaction was reported on 14 August 2026 (Levée d'options). Among the most active insiders: Colangelo Dominick. The full history is openly available.
232
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€5m
37 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Vericel Corp Strong Buy (bullish), based on 7 analysts. Average price target: US$60.57.
35Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 16,038 of 29,062 companies
49.1
score / 100
Value41
Quality57
FCF yld1.2%
Earn yld0.8%
EV/EBITDA·
ROE7.2%
Gross mgn74%
Net mgn6.0%
Debt/EBITDA3.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 14 August 2026
Declarations232 total
7,000 shares@ US$13.05Common StockSEC:0001140361-26-033143:0
7,000 shares@ US$44.53Common StockSEC:0001140361-26-033143:1
7,000 shares@ US$44.110.014% mcap66.2% of flowCommonSEC144:0001959173-26-005916
10,000 shares@ US$16.660.0071% mcap5.6% of flowCommon StockSEC:0001140361-26-031417:0
10,000 shares@ US$46.840.020% mcap15.6% of flowCommon StockSEC:0001140361-26-031417:1
10,000 shares@ US$45.980.019% mcap19.5% of flowCommonSEC144:0001959173-26-005511
1,500 shares@ US$34.900.0022% mcap4.2% of flowCommon StockSEC:0001140361-26-030487:0
1,500 shares@ US$48.900.0031% mcap5.9% of flowCommon StockSEC:0001140361-26-030487:1
2,500 shares@ US$29.820.0031% mcap6.0% of flowCommon StockSEC:0001140361-26-030487:2
2,500 shares@ US$48.900.0052% mcap9.8% of flowCommon StockSEC:0001140361-26-030487:3
500 shares@ US$29.820.0006% mcap1.2% of flowCommon StockSEC:0001140361-26-030487:4
500 shares@ US$48.900.0010% mcap2.0% of flowCommon StockSEC:0001140361-26-030487:5
4,500 shares@ US$48.900.0093% mcap24.7% of flowCommonSEC144:0001959173-26-005454
5,000 sharesCommon StockSEC:0001140361-26-026931:0
15,000 sharesCommon StockSEC:0001140361-26-026929:0
15,000 sharesCommon StockSEC:0001140361-26-026929:1
5,000 sharesCommon StockSEC:0001140361-26-026930:0
5,000 sharesCommon StockSEC:0001140361-26-026930:1
5,000 sharesCommon StockSEC:0001140361-26-026930:2
5,000 sharesCommon StockSEC:0001140361-26-026930:3
15,000 shares@ US$45.64390.029% mcap25.9% of flowCommonSEC144:0001959173-26-004925
10,000 shares@ US$45.000.019% mcap27.1% of flowCommonSEC144:0001959173-26-004921
5,000 shares@ US$44.750.0094% mcap19.2% of flowCommonSEC144:0001959173-26-004924
2,732 shares@ US$44.900.0051% mcap18.5% of flowCommonSEC144:0001959173-26-004922
15,000 shares@ US$40.20990.025% mcap18.5% of flowCommonSEC144:0001959173-26-004780
25 of 232 declarations
关于 Vericel Corp
Vericel Corp. (NASDAQ:VCEL) 是一家在美国纳斯达克市场上市的美国商业阶段生物技术和再生医学公司。公司总部位于美国马萨诸塞州剑桥，已从其最初的 Aastrom Biosciences 发展成为一个专注于自体细胞疗法的专业生物制剂平台，用于高度专业化、高价值的适应症。现代 Vericel 的故事在 2014 年品牌重塑后形成，当时公司转向市场化产品，并摆脱了纯粹的开发阶段形象。([investors.vcel.com](https://investors.vcel.com/news-releases/news-release-details/aastrom-biosciences-changes-name-vericel-corporation?utm_source=openai)) Vericel 的业务围绕三个核心产品展开。MACI 是其旗舰产品，通过自体细胞疗法修复膝关节有症状的软骨缺损。Epicel 是一种用于深层真皮或全层烧伤患者的永久性皮肤替代产品，使 Vericel 在严重烧伤护理领域占据了利基市场。NexoBrid 获得了北美商业权利许可，将产品组合扩展到严重热烧伤的酶促清创术。这些产品共同使 Vericel 处于一个高度专业化的细分市场，该市场具有显著的监管壁垒、复杂的制造要求以及与骨科和烧伤中心的牢固关系。([vcel.com](https://www.vcel.com/about/?utm_source=openai)) 从竞争角度来看，Vericel 之所以脱颖而出，是因为很少有公司在运动医学软骨修复和严重烧伤治疗方面都有类似的业务。公司强调其自体细胞疗法专业知识、在美国深厚的商业基础设施以及制造技术是其关键差异化因素。一项重要的战略发展是位于马萨诸塞州伯灵顿的新制造和公司总部设施，该设施旨在扩大细胞疗法产能并支持 MACI 和 Epicel 的长期增长。公司最近的沟通表明该设施已竣工，预计将于 2026 年开始商业化生产。([investors.vcel.com](https://investors.vcel.com/news-releases/news-release-details/vericel-announces-plans-new-state-art-cell-therapy-manufacturing?utm_source=openai)) 对于投资者而言，吸引力在于 MACI 的商业可见性、Vericel 利基市场相对可防御的性质以及额外制造能力带来的运营上行空间。公司 2025 年的更新强调了强劲的收入势头和改善的盈利能力，这得益于 MACI 和 NexoBrid 在烧伤护理中日益增长的贡献。作为一家纳斯达克上市的美国医疗保健小型股公司，Vericel 提供了集中的产品组合、清晰的战略重点和主要国内的商业足迹。([investors.vcel.com](https://investors.vcel.com/news-releases/news-release-details/vericel-reports-first-quarter-2025-financial-results-and-raises?utm_source=openai))
